Drugs
Drugs we follow
23 drugs from the biotech companies we cover, each with who develops it, where it is approved, its development by disease and its next dated event.
- Aficamten · CYTK · approvedNext: the FDA decision on Aficamten (supplemental application), Nov 14
- ANKTIVA (nogapendekin alfa inbakicept) · IBRX · approvedNext: the FDA decision on ANKTIVA (supplemental application), Jan 6
- Bepirovirsen · IONSNext: the FDA decision on Bepirovirsen, Oct 26
- D-PLEX100 · PYPDNext: the FDA decision on D-PLEX 100, Nov 28
- Deramiocel · CAPRNext: the FDA decision on Deramiocel, Nov 22
- Encaleret · BBIONext: the FDA decision on Encaleret, May 8
- Ivonescimab · SMMT · approvedNext: the FDA decision on Ivonescimab, Nov 14
- Lifileucel · IOVA · approvedNext: Phase 2 updated results (IOV-COM-202) for Lifileucel, October 2026
- Lonvoguran ziclumeran (NTLA-2002) · NTLANext: the FDA decision on NTLA-2002, Mar 10
- Mitapivat · AGIO · approvedNext: the FDA decision on Mitapivat (supplemental application), Nov 1
- Mivocabtagene autoleucel (miv-cel) · KYTXNext: Phase 1 results for Miv-cel, Q4 2026
- Nomlabofusp · LRMRNext: BLA submission for Nomlabofusp, H2 2026
- Obecabtagene autoleucel (obe-cel) · AUTL · approvedNext: Phase 1 long-term results (CARLYSLE) for Obe-cel, Q4 2026
- Phentolamine ophthalmic solution 0.75% · IRD · approvedNext: Phase 3 topline results (LYNX-3) for Phentolamine Ophthalmic Solution, October 2026
- QTORIN rapamycin · PVLANext: Phase 3 start for QTORIN rapamycin, Q4 2026
- Relutrigine · PRAXNext: the FDA decision on Relutrigine, Dec 27
- Rexaceract · GANXNext: Regulatory submission for Rexaceract, Q4 2026
- Seralutinib · GOSSNext: the FDA decision on Seralutinib, Q3 2027
- Tinlarebant · BLTENext: the FDA decision on Tinlarebant, Feb 12
- Ulixacaltamide · PRAXNext: the FDA decision on Ulixacaltamide, Jan 29
- VK2735 · VKTXNext: Phase 3 start for Oral VK2735, Q4 2026
- Vusolimogene oderparepvec (RP1) · REPL · approved
- Zipalertinib · CGEMNext: the FDA decision on Zipalertinib, Feb 27